The Europe Blood Glucose Monitoring Market Report is Segmented by Device Type (Self-Monitoring Blood Glucose Devices [Glucometer Devices, Test Strips, and Lancets] and Continuous Glucose Monitoring Devices [Sensors and Durables]), End User (Home Healthcare, Hospitals & Clinics, and Pharmacies & Others), and Geography (Germany, France, United Kingdom, Italy, Spain and More). The Market Forecasts are Provided in Terms of Value (USD).

Snapshot img

Blood Glucose Monitoring Devices Market Size 2025-2029

The blood glucose monitoring devices market size is forecast to increase by USD 10.14 billion at a CAGR of 10% between 2024 and 2029.

The market is experiencing significant growth, driven by the rising global burden of diabetes and the increasing adoption of advanced technologies such as smart watch-based apps for continuous glucose monitoring. According to the International Diabetes Foundation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. This growing population of diabetes patients presents a substantial market opportunity for blood glucose monitoring device manufacturers. However, the market faces challenges that could hinder its growth potential. Regulatory hurdles impact adoption, as these devices must meet stringent regulatory requirements to ensure accuracy and safety.
Additionally, supply chain inconsistencies can pose challenges, as the demand for these devices is often volatile and requires a reliable and flexible supply chain to meet patient needs effectively. To capitalize on market opportunities and navigate these challenges, companies must focus on regulatory compliance, supply chain optimization, and the development of user-friendly and accurate devices that meet the evolving needs of diabetes patients. Technological advances in this field have led to more sophisticated devices, such as continuous glucose monitoring systems, insulin syringe and pens, which offer enhanced functionality and improved patient outcomes. The hospital end-use segment supports inpatient monitoring, while home healthcare segment devices empower individuals with convenient glucose monitoring solutions. By addressing these challenges, market participants can position themselves for long-term success in the market.

What will be the Size of the Blood Glucose Monitoring Devices Market during the forecast period?

Request Free Sample

The market is experiencing significant growth, driven by the increasing prevalence of diabetes and the demand for advanced technologies to support personalized diabetes management. Patient engagement is a key trend, with diabetes prevention programs emphasizing diet and exercise, and digital health solutions enabling remote patient monitoring through the Internet of Things. Artificial intelligence and machine learning are revolutionizing data analytics, enabling early detection of diabetes complications and improving quality of life through data interpretation. Diabetes research continues to advance, with innovation in sensor calibration and cloud computing enhancing the accuracy and accessibility of blood glucose monitoring.
The market encompasses a range of essential tools including glucose meters, lancets, and test strips, crucial for managing conditions like Type 2 diabetes. Innovations like Insulin pumps and Continuous Glucose Monitoring (CGM) systems such as Eversense CGM utilize advanced sensor technologies and microminiaturization. Diabetes awareness and education programs are also crucial, leveraging digital platforms to reach larger audiences and promote lifestyle modifications. Overall, the market is dynamic and innovative, with a focus on improving diabetes management and preventing complications.

How is this Blood Glucose Monitoring Devices Industry segmented?

The blood glucose monitoring devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals
  Home care
  Diagnostic centers


Product

  SMBG
  CGM
  Lancets


Indication

  Type-2 diabetes population
  Type-1 diabetes population


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

The diabetes care market encompasses various devices and technologies used for managing diabetes, with blood glucose monitoring devices being a crucial component. These devices include blood glucose meters, continuous glucose monitoring systems like Guardian Connect and Dexcom G6, and non-invasive glucose monitoring solutions. Diabetes educators and primary care physicians often recommend these tools for individuals with diabetes, including those with type 1, type 2, and gestational diabetes. Blood glucose meters provide instant readings, while continuous glucose monitoring systems offer real-time data logging and predictive capabilities. Wearable technology, such as insulin pumps and flash glucose monitoring systems like the Freestyle Libre, enable remote monitoring and data analysis

Access Europe Glucose Monitoring Devices Industry Overview which includes Europe country analysis of (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe), market split by Device Type, End User, Patient Type

The Report Covers Europe Blood Glucose Monitoring Market Trends and the Market is Segmented by Components (glucometer Devices, Test Strips, And Lancets) and Geography (France, Germany, Italy, Rest of Europe, Russia, Spain, United Kingdom). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

The Europe Blood Glucose Monitoring Devices market was valued at USD 4 Billion in 2022 due to growing health awareness.

The size of the Europe Blood Glucose Monitoring Market market was valued at USD 3.14 Million in 2023 and is projected to reach USD 4.84 Million by 2032, with an expected CAGR of 6.38% during the forecast period. This Europe Blood Glucose Monitoring Market is growing due to the increase in the incidences of diabetes the growing awareness of managing diabetes. Self-actualization, monitoring tools such as blood glucose monitoring devices enables people with diabetes maintain correct schedules of check-ups for their blood sugar level. Some of the self-monitoring devices are glucometers, CGMS and SMBG equipment. The trends that emerged over the course of the past few years focus on the use of sophisticated digital health technologies that are Bluetooth compatible and may connect to the patient’s smartphone. This is because markets are advancing in technology hence the technological developments are reaching the market, there is a rising trend in the investment in the healthcare sector, and the demand for systems that offer minimal invasions and painless monitoring is also on the rise. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published improved glycemic control using a Bluetooth-connected blood glucose meter and a mobile diabetes app: Real-World Evidence from over 144,000 people with diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas pulse includes an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It's designed to be used with patients of all ages, including neonates and people in intensive care.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Increasing Diabetes Prevalence is Driving the Europe self-monitoring Blood Glucose Devices Market in forecast period.

The size of the Europe Continuous Glucose Monitoring Market was valued at USD 2.04 Million in 2023 and is projected to reach USD 4.32 Million by 2032, with an expected CAGR of 11.33% during the forecast period. The Europe CGM market has been growing at a fast rate due to factors such as increased incidence of diabetes, innovation, and growing awareness on diabetes control. Thus, CGM is an accurate approach to obtaining real-time data of blood glucose levels in people with diabetes, which helps to adhere to an optimal glycemic targeting and, therefore, minimize the risk of development of complications. These devices are self-administered by the patients, and are used in hospitals and clinic across the world. The demand is also propelled by governments that take efforts to encourage the proper care of diabetes and technological development and trends towards wearable devices. These trends encompass the use of Artificial Intelligence, analytics of data, and enhanced accuracy of the sensors. Specific uses are in type 1 and type 2 diabetes treatments, and the appliance is being used more frequently in children. Recent developments include: October 2023: Medtronic has recently introduced Simplera, a cutting-edge CGM designed for individuals with diabetes aged 2 and above. Currently undergoing FDA evaluation for clearance in the United States, Simplera boasts a modern, disposable design and eliminates the need for fingersticks., June 2022: Ascensia Diabetes Care, maker of the Contour blood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that its partner Senseonics Holdings, Inc., received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Continuous Glucose Monitoring Devices Prove to be an Instrumental Tool in maintaining Glycemic Balance.

The report on Eastern Europe Glucose Monitoring Devices covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

The Report Covers Continuous Glucose Monitoring Companies and It is Segmented by Components (sensors and Durables) and Geography (France, Germany, Italy, Spain, Russia, The United Kingdom, And the Rest of Europe). The Market Values are Provided (in USD) and Volume (in Units) for the Above Segments.

The European blood glucose monitoring market, valued at €3.14 billion in 2025, is projected to experience robust growth, driven by the rising prevalence of diabetes across the region. A compound annual growth rate (CAGR) of 6.38% from 2025 to 2033 indicates a significant market expansion, fueled by several key factors. Increased awareness of diabetes management, coupled with advancements in technology leading to more accurate and user-friendly glucometers, test strips, and lancets, are primary drivers. The aging population in Europe, a significant risk factor for diabetes, further contributes to market growth. Furthermore, the increasing adoption of continuous glucose monitoring (CGM) systems, offering real-time data and improved patient management, is expected to significantly impact market segmentation and growth trajectory over the forecast period. However, high costs associated with CGM technology and the availability of less expensive alternative monitoring methods might act as market restraints to some extent. The market is segmented by component into glucometer devices, test strips, and lancets, with significant variations in market share among these components. Leading players like Abbott Diabetes Care, Roche Diabetes Care, and LifeScan, hold substantial market shares, leveraging their established brand recognition and extensive distribution networks. The market demonstrates a strong regional disparity within Europe, with countries like Germany, France, and the UK likely contributing the largest shares, driven by higher diabetes prevalence and better healthcare infrastructure compared to other regions. The competitive landscape is characterized by both established multinational companies and smaller regional players. Strategic alliances, mergers and acquisitions, and technological innovation are prominent strategies employed by market players to gain a competitive edge. The forecast period from 2025 to 2033 promises sustained growth, propelled by the continued rise in diabetes prevalence and the ongoing development of innovative blood glucose monitoring technologies. While pricing pressures and regulatory hurdles may present challenges, the overall outlook for the European blood glucose monitoring market remains positive, promising significant opportunities for market participants. Further analysis of specific regional markets (France, Germany, Italy, Spain, UK, Russia, and Rest of Europe) would provide granular insights into market dynamics and inform targeted strategies. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published improved glycemic control using a Bluetooth-connected blood glucose meter and a mobile diabetes app: Real-World Evidence from over 144,000 people with diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas pulse includes an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It's designed to be used with patients of all ages, including neonates and people in intensive care.. Notable trends are: Increasing Diabetes Prevalence is Driving the Europe self-monitoring Blood Glucose Devices Market in forecast period.

In Europe Glucose Monitoring Devices Market , was valued at approximately USD 10.11 billion in 2022 and is projected to reach USD 12.45 billion by 2029,

The Europe Veterinary Glucose Monitoring Devices Market would witness market growth of 7.1% CAGR during the forecast period (2024-2031). The Germany market dominated the Europe Veterinary Glucose Monitoring Devices Market by Country in 2023, and would continue to be a dominant market till 2031; th

The Europe Diabetic Care Devices Market is projected to reach a value of 8.03 million by 2025, exhibiting a CAGR of 6.18% during the forecast period 2019-2033. Growth in the market is attributed to factors such as the increasing prevalence of diabetes, growing awareness about blood glucose monitoring, and technological advancements in diabetic care devices. The rising incidence of diabetes coupled with the surging geriatric population are major factors driving the growth of the Europe Diabetic Care Devices Market. Moreover, government initiatives and reimbursement policies are further contributing to market growth. Key trends influencing market growth include the increasing adoption of continuous glucose monitoring devices, the integration of mobile health technology, and the growing focus on personalized diabetes management. However, factors such as high costs associated with diabetic care devices, potential risks associated with their usage, and the availability of generic drugs may restrain market growth to some extent. The Europe Diabetic Care Devices Market is segmented based on monitoring devices, management devices, companies, and region. The monitoring devices segment is further sub-segmented into self-monitoring blood glucose devices and continuous glucose monitoring devices. The self-monitoring blood glucose devices segment holds a significant market share due to the wide use of glucometer devices by diabetic patients. The insulin pumps segment is expected to witness significant growth during the forecast period due to the rising adoption of insulin therapy. Recent developments include: Feburary 2024: Dexcom launched real-time CGM solution Dexcom ONE+ in Europe. Dexcom ONE+ is a customisable continuous glucose monitoring solution that can be worn at three different location on the body., June 2022: Cequr, the leader in wearable diabetes technology, released its newest and most innovative insulin delivery device, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body, and it also features a built-in blood glucose meter so that users can track their blood sugar throughout the day.. Key drivers for this market are: Increasing Demand for Better Dentistry and Better Aesthetic outcomes, Increase in the Disposable Income. Potential restraints include: High Cost Associated with the Digital Dentistry. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

Snapshot img

Non-Invasive Glucose Monitoring Devices Market Size 2025-2029

The non-invasive glucose monitoring devices market size is forecast to increase by USD 43.7 million, at a CAGR of 20.4% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing prevalence of diabetes and initiatives by governments to promote diabetes management through advanced technologies. This trend is expected to continue as the global diabetes population continues to rise, necessitating the need for more effective and convenient glucose monitoring solutions. However, the market faces challenges, including the occasional recalls of non-invasive glucose monitoring devices due to quality concerns. These incidents can negatively impact market trust and consumer confidence, necessitating stricter regulatory oversight and quality control measures. Non-invasive glucose monitoring devices utilize transdermal sensors and near-infrared (NI) light to measure glucose levels through the skin, eliminating the need for invasive procedures.
To capitalize on the market's potential, companies must prioritize product innovation, regulatory compliance, and robust quality control systems to differentiate themselves and build consumer trust. Additionally, strategic collaborations and partnerships can facilitate business expansion and market penetration, enabling companies to leverage each other's expertise and resources to address the evolving needs of the diabetes population. With the increasing focus on precision agriculture, the market for non-invasive glucose monitoring devices is expected to continue its growth trajectory.

What will be the Size of the Non-Invasive Glucose Monitoring Devices Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market is experiencing significant growth due to the value proposition these offer to medical device companies and biotechnology firms. Electrochemical sensors and optical sensors are leading the technology landscape, driving research and development in this sector. Patients seek non-invasive methods for monitoring their glucose levels to facilitate lifestyle modifications, exercise regimens, and dietary changes. Customer retention is crucial for market players, leading to innovation in areas like smartphone integration, data storage, Bluetooth connectivity, ,data sharing and digital monitoring. Product differentiation is essential, as companies strive to offer unique features and pricing strategies to boost brand awareness.
The market is witnessing an increase in interstitial fluid monitoring devices, providing real-time, continuous glucose readings without the need for frequent finger-prick tests. Wireless communication and patient education are also key trends, enabling better disease management and improved patient outcomes. The distribution channels for these devices are expanding, making non-invasive glucose monitoring more accessible to a wider population. These devices offer farmers the ability to monitor plant health status, make informed agronomic decisions, and manage inputs such as fertilizers and water usage effectively.

How is this Non-Invasive Glucose Monitoring Devices Industry segmented?

The non-invasive glucose monitoring devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Wearable
  Non-wearable


End-user

  Home care settings
  Hospitals
  Clinics


Component

  Measuring device
  Transmitter
  Software or app


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    India


  South America

    Brazil


  Rest of World (ROW)

By Product Insights

The wearable segment is estimated to witness significant growth during the forecast period. Wearable non-invasive glucose monitoring devices, utilizing transdermal sensors and near-infrared (NI) light technology, dominate the global market. These devices, which do not require needles or invasive procedures, have gained significant traction among diabetic patients, particularly those with diabetes who endure the inconvenience of frequent finger pricks for blood sugar level checks. The continuous glucose monitoring offered by non-invasive wearables is more comfortable and convenient, contributing to better diabetes management. Cloud computing integration enables real-time data access and analysis, while remote monitoring empowers healthcare providers to closely monitor their patients' glucose levels. Data visualization and predictive analytics help patients and healthcare professionals interpret compl

The European Continuous Glucose Monitoring (CGM) market is experiencing robust growth, projected to reach €2.04 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 11.33% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of diabetes, particularly type 1 and type 2, across Europe fuels demand for advanced glucose monitoring solutions. CGM systems offer superior accuracy and real-time data compared to traditional methods, empowering individuals to manage their condition more effectively and reduce the risk of severe hypoglycemic or hyperglycemic events. Technological advancements, including smaller, more comfortable sensor designs and improved data integration with mobile applications and insulin pumps, are further boosting market adoption. Government initiatives promoting diabetes management and reimbursement policies covering CGM devices also contribute to market growth. The market is segmented into sensors and durables, with sensors representing a significant portion due to recurring purchase needs. Key players like Abbott, Dexcom, Medtronic, and Senseonics are driving innovation and market competition, leading to improved product offerings and price competitiveness. The market is expected to witness particularly strong growth in countries such as Germany, the United Kingdom, and France, given their larger diabetic populations and well-established healthcare infrastructure. The competitive landscape is characterized by intense rivalry amongst established players and emerging companies. Market share analysis suggests a concentrated market with Abbott, Dexcom, and Medtronic holding a substantial portion. However, the presence of other players and ongoing innovations indicate a dynamic market with opportunities for both established players and new entrants. Restraints to market growth include high device costs, potential sensor inaccuracies in certain situations, and concerns about data privacy and security. Despite these challenges, the overall growth trajectory remains positive, underpinned by the unmet medical need and continuous technological improvements in CGM technology. Future growth will be significantly influenced by the development of advanced analytics, integration with artificial intelligence for personalized diabetes management, and expansion of access to CGM across various healthcare settings. Recent developments include: October 2023: Medtronic has recently introduced Simplera, a cutting-edge CGM designed for individuals with diabetes aged 2 and above. Currently undergoing FDA evaluation for clearance in the United States, Simplera boasts a modern, disposable design and eliminates the need for fingersticks., June 2022: Ascensia Diabetes Care, maker of the Contour blood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that its partner Senseonics Holdings, Inc., received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries.. Notable trends are: Continuous Glucose Monitoring Devices Prove to be an Instrumental Tool in maintaining Glycemic Balance.

Europe Diabetes Care Devices Market size was valued at USD 8.40 Billion in 2024 and is expected to reach USD 14.65 Billion by 2032, growing at a CAGR of 7.2% from 2026 to 2032.

Europe Diabetes Care Devices Market: Definition/ Overview

Diabetes care devices are medical instruments and equipment that assist diabetics in monitoring and regulating their blood sugar (glucose) levels properly. These gadgets help diabetics maintain glycemic control, avoid problems, and improve their quality of life. They are mostly utilized by patients, healthcare providers, and caregivers.

Europe Blood Glucose Monitoring Market size was valued at USD 6.19 Billion in 2023 and is projected to reach USD 10.40 Billion by 2031, growing at a CAGR of 6.7% from 2024 to 2031.

Europe Blood Glucose Monitoring Market Dynamics

The key market dynamics that are shaping the Europe blood glucose monitoring market include:

Key Market Drivers Rising Diabetes Prevalence: According to the IDF, the prevalence of diabetes in Europe is rapidly increasing, with around 61 million adults presently living with the disease and a projected 67 million by 2045.

The European diabetic care devices market is experiencing robust growth, projected to reach €8.03 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 6.18% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of diabetes across Europe, driven by increasing obesity rates and aging populations, creates significant demand for effective diabetes management tools. Furthermore, technological advancements in continuous glucose monitoring (CGM) systems and insulin delivery devices, offering improved accuracy, convenience, and patient outcomes, are driving market growth. Increased awareness of the benefits of self-monitoring blood glucose (SMBG) and the rising adoption of telehealth solutions for diabetes management are also contributing factors. The market is segmented by device type (e.g., SMBG devices, insulin pumps, CGM devices), with CGM experiencing particularly strong growth due to its minimally invasive nature and real-time data provision. Competition among established players such as Abbott Diabetes Care, Roche Diabetes Care, and Medtronic, as well as emerging innovative companies, is fostering innovation and affordability. Despite the growth potential, market expansion faces certain challenges. High costs associated with advanced devices like CGMs remain a barrier to entry for some patients. Furthermore, ensuring consistent patient adherence to treatment regimens and addressing potential device-related complications are ongoing concerns. Regulatory hurdles and reimbursement policies across different European countries can also influence market dynamics. However, the long-term outlook remains positive, driven by continued technological progress and increasing healthcare spending dedicated to managing chronic conditions like diabetes. The market is poised for considerable expansion, with continued innovation expected to improve patient lives and make diabetes management more efficient and effective across the continent. Key drivers for this market are: Increasing Demand for Better Dentistry and Better Aesthetic outcomes, Increase in the Disposable Income. Potential restraints include: High Cost Associated with the Digital Dentistry. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

The global blood glucose monitoring (BGM) market, valued at $2.98 billion in 2025, is projected to experience robust growth, driven by rising prevalence of diabetes, an aging global population, and increasing adoption of continuous glucose monitoring (CGM) systems. The market's compound annual growth rate (CAGR) of 8.5% from 2025 to 2033 indicates significant expansion opportunities. Key drivers include the convenience and improved health outcomes associated with CGM, growing awareness of diabetes management, and technological advancements leading to smaller, more accurate, and user-friendly devices. Furthermore, the increasing availability of affordable BGM devices in emerging economies is fueling market growth. However, the market faces restraints such as the high cost of CGM systems, particularly in low- and middle-income countries, and potential inaccuracies in some self-monitoring blood glucose (SMBG) devices. The market is segmented into SMBG, CGM, and lancets, with CGM experiencing the fastest growth due to its continuous data provision enabling proactive diabetes management. Leading companies like Abbott Laboratories, Dexcom Inc., and Medtronic Plc are aggressively pursuing market share through product innovation, strategic partnerships, and expansions into new geographic markets. Competitive strategies focus on technological advancements, improved accuracy, data integration with mobile applications, and development of user-friendly interfaces. Industry risks include stringent regulatory approvals, intense competition, and potential cybersecurity concerns related to data privacy in connected devices. The regional distribution of the market reflects varying levels of diabetes prevalence and healthcare infrastructure. North America currently holds a significant market share due to high diabetes prevalence and advanced healthcare systems. However, the Asia-Pacific region is expected to witness considerable growth in the forecast period driven by rising diabetes rates in countries like India and China, coupled with increasing disposable incomes and improved healthcare access. Europe and other developed regions will maintain steady growth, primarily driven by technological upgrades and increased adoption of sophisticated monitoring systems. The competitive landscape is characterized by both established players and emerging companies offering innovative solutions. Successful companies will continue to focus on enhancing the accuracy and ease of use of their devices while emphasizing data-driven insights for better patient outcomes.

The size of the U.S. Continuous Glucose Monitoring Devices Market market was valued at USD 1.62 billion in 2023 and is projected to reach USD 2.55 billion by 2032, with an expected CAGR of 6.68 % during the forecast period. The U. S. Continuous Glucose Monitoring (CGM) Devices Market is aimed at portable devices that can track the glucose levels of diabetic patients in real-time manner. These devices use a system to monitor glucose level every now and then at different time inclusive of day and night with trends and alarms for high and low glucose. They are also employed in diabetes care to enhance the management of diabetes and control the patients’ glycemic profiles. The market is continuously experiencing the uptake of CGM systems because they are accurate, convenient and new technologies like the integration of the systems with smartphones and insulin pumps. Some of the important trends include demand for wearable devices, the evolution of sensors and increasing consciousness of consumers about diabetes. Recent developments include: In February 2024, DexCom announced the launch of a unique CGM device, DexCom ONE+ in Europe. This device would allow real-time monitoring of blood glucose to users through a smartphone app. , In January 2024, Abbott and Tandem Diabetes Care, Inc. recently announced that their t:slim X2 insulin pump, which uses Control-IQ technology, has become the first Automated Insulin Delivery (AID) system to integrate with Abbott's latest Continuous Glucose Monitoring (CGM) technology, the FreeStyle Libre 2 Plus sensor. This development has enabled users of FreeStyle Libre technology in the U.S. to experience the benefits of a hybrid closed-loop system. With this system, users can predict and prevent high & low blood sugar levels , In October 2023, Phillips-Medisize announced the collaboration with GlucoModicum to present a non-invasive CGM wearable device to provide better patient outcomes. , In February 2023, Dexcom launched the Dexcom G7 CGM System in the U.S. It introduced the CGM system through a Super Bowl commercial starring Nick Jonas, who has diabetes. The commercial was expected to be watched by over 4.8 million diabetic U.S. individuals, of which 3.3 million were not using CGM and 2.3 million had CGM coverage. Hence, the ad was expected to create awareness about diabetes and have an influential product launch. .